As shown in Table 3, correlations between CEP55 expression and clinical stage, lymph node metastasis, intraperitoneal metastasis, tumor recurrence, differentiation grade, residual tumor size, serum CA153 level, and ascites see tumor cells were 0.550 (P < 0.001), 0.328 (P < 0.001), 0.414 (P < 0.001), 0.607 (P < 0.001), 0.251 (P < 0.001), 0.235 (P < 0.001), 0.289 (P < 0.001), and 0.157 (P = 0.020), respectively. Here, CEP55 is linked to metastatic malignant neoplasm in the lymph nodes.